55个品种、可按厂牌报量，第十一批国家药品集采报量启动

Core Viewpoint - The eleventh batch of national organized drug procurement has officially launched, involving 55 varieties of drugs, with optimized reporting rules to enhance participation from medical institutions [1] Group 1: Drug Procurement Details - The new reporting rules allow medical institutions to report demand based on generic names without distinguishing brands, or to specify brands, encouraging participation from recognized companies [1] - Each medical institution is required to report an annual demand of no less than 80% of the average usage for the 2023-2024 period for each drug variety [1] - Medical institutions can provide written explanations for significant decreases in expected usage due to clinical demand changes or business adjustments, allowing for actual demand reporting [1] Group 2: Special Considerations - The reporting system includes specific annotations for essential drug specifications, allowing institutions to determine conversion ratios if the specification has not passed quality and efficacy consistency evaluations [1] - For pediatric formulations that have not passed consistency evaluations and are deemed irreplaceable, institutions can report based on actual needs with appropriate explanations [1]